“EW has become a partner and advisor to Abiomed. We value the strategic guidance we receive from their team on investment and business decisions.”
Michael R. Minogue
Chairman, President and CEO, Abiomed
Produces the Impella product line, the world's smallest, minimally invasive, high performance micro blood pump
Leading provider of mechanical circulatory support devices, offering a continuum of care to heart failure patients
Abiomed (Nasdaq: ABMD) develops products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its main family of products, Impella, is used in the cardiac catheterization lab by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Company’s main products include Impella 2.5, Impella 5.0, Impella CP, Impella RP, and Symphony. Abiomed generated FY 2013 Sales of ~$160M. The Company was founded in 1981, sells its products around the globe, and has over 500 employees.
“EW has become a partner and advisor to Abiomed. We value the strategic guidance we receive from their team on investment and business decisions.”
Chairman, President and CEO, Abiomed